- Switch from biosimilar infliximab CT-P13 to biosimilar infliximab SB-2 in the long-term maintenance therapy in IBD patients - prospective observational study2023 | First Faculty of Medicine
- Biosimilars in treating inflammatory rheumatic diseases2015 | First Faculty of Medicine
- Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis2016 | First Faculty of Medicine, Second Faculty of Medicine
- Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis2016 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Second Faculty of Medicine, Third Faculty of Medicine
- Serum trough infliximab levels: A comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease2016 | First Faculty of Medicine
- Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort2018 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort2017 | First Faculty of Medicine
- Biosimilar infliximab in a clinical laboratory practice2016 | First Faculty of Medicine
- Patient Access, Unmet Medical Need, Expected Benefits, and Concerns Related to the Utilisation of Biosimilars in Eastern European Countries: A Survey of Experts2018 | Faculty of Pharmacy in Hradec Králové
- Biosimilar drugs: what a rheumatologist should know2023 | First Faculty of Medicine
- Pregnancy outcomes in women with inflammatory bowel disease treated with biosimilar infliximab2018 | First Faculty of Medicine